# Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

Study · id `cardio:ct-nct03062319` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03062319](<https://clinicaltrials.gov/study/NCT03062319>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03062319

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 321 participants.

## Technical summary

Registry record NCT03062319. Randomized; no masking; primary purpose prevention. Start 2017-04-06 (actual); primary completion 2023-07-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 321 participants (enrolled count; ClinicalTrials.gov record NCT03062319, source copy `cardio:ctgov-nct03062319-2024-12-27`, retrieved 2026-10-26)
- Started: 2017-04-06 (actual) (ClinicalTrials.gov record NCT03062319, source copy `cardio:ctgov-nct03062319-2024-12-27`, retrieved 2026-10-26)
- Primary completion: 2023-07-18 (actual) (ClinicalTrials.gov record NCT03062319, source copy `cardio:ctgov-nct03062319-2024-12-27`, retrieved 2026-10-26)
- Completion: 2023-07-18 (actual) (ClinicalTrials.gov record NCT03062319, source copy `cardio:ctgov-nct03062319-2024-12-27`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03062319, source copy `cardio:ctgov-nct03062319-2024-12-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03062319-2024-12-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
- Acronym: ATIS-NVAF
- Condition: Ischemic Stroke
- Condition: Atrial Fibrillation
- Condition: Atherothrombosis
- Intervention (Drug): Oral Anticoagulant
- Intervention (Drug): Antiplatelet Drug
- Lead sponsor: National Hospital Organization Osaka National Hospital
- Lead sponsor class: OTHER
- Collaborator: Network for Clinical Stroke Trials
- Collaborator class: UNKNOWN
- Collaborator: The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial (`cardio:pubmed-41051787`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 370fe4bb52dc92cbfc49a3a6dbb21c088a875a32465d4e071e993bb16b366e02
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
